Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

New Targetable Oncogenes in Non–Small-Cell Lung Cancer

(2013) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Corticosteroids plus Long-Acting Beta2-Agonists Prevent Double-Stranded RNA-Induced Upregulation of B7-H1 on Airway Epithelium

(2012) K. Kan-o et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Improved Endpoints for Cancer Immunotherapy Trials

(2010) A. Hoos et al.   JNCI-Journal of the National Cancer Institute